Targeting the TGR5-GLP-1 pathway to combat type 2 diabetes and non-alcoholic fatty liver disease

T W H Pols; J Auwerx; K Schoonjans

doi:10.1016/j.gcb.2010.03.009

Targeting the TGR5-GLP-1 pathway to combat type 2 diabetes and non-alcoholic fatty liver disease

Gastroenterol Clin Biol. 2010 Apr-May;34(4-5):270-3. doi: 10.1016/j.gcb.2010.03.009. Epub 2010 May 4.

Authors

T W H Pols¹, J Auwerx, K Schoonjans

Affiliation

¹ Laboratory of Integrative and Systems Physiology (LISP), Ecole Polytechnique Fédérale de Lausanne, 1015 Lausanne, Switzerland.

PMID: 20444564
DOI: 10.1016/j.gcb.2010.03.009

Abstract

Incretin-based therapies have shown promise in the treatment of type 2 diabetes. Here we review our current understanding of TGR5 as a target to induce glucagon-like peptide-1 (GLP-1) secretion. These new observations suggest that TGR5 agonists may constitute a novel approach to treat type 2 diabetes, as well as complications of diabetes, such as non-alcoholic fatty liver disease.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Diabetes Mellitus, Type 2 / drug therapy*
Diabetes Mellitus, Type 2 / metabolism*
Dipeptidyl-Peptidase IV Inhibitors / pharmacology
Glucagon-Like Peptide 1 / analogs & derivatives
Glucagon-Like Peptide 1 / metabolism
Glucose / metabolism
Humans
Receptors, G-Protein-Coupled / agonists*
Receptors, G-Protein-Coupled / physiology

Substances

Dipeptidyl-Peptidase IV Inhibitors
Receptors, G-Protein-Coupled
Glucagon-Like Peptide 1
Glucose